StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) stock

RDHLNasdaqPharmaceutical Preparations
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35+0.00 (0.00%)

Close on Nov 18, 2026Market cap $1.78MP/E –Yield –

RedHill Biopharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

For fiscal 2025 it was $286.00K, down 96.4% from the year before. Over ten years it grew 57.7% a year on average. The highest annual figure on record is $85.76M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$286.00K-96.4%
FY2024Dec 31, 2024$8.04M+23.2%
FY2023Dec 31, 2023$6.53M-89.4%
FY2022Dec 31, 2022$61.80M-27.9%
FY2021Dec 31, 2021$85.76M+33.2%
FY2020Dec 31, 2020$64.36M+923.0%
FY2019Dec 31, 2019$6.29M-24.7%
FY2018Dec 31, 2018$8.36M+108.6%
FY2017Dec 31, 2017$4.01M+3867.3%
FY2016Dec 31, 2016$101.00K+3266.7%
FY2015Dec 31, 2015$3.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2022Jun 30, 2022$18.35M+680.7%
Q2 FY2021Jun 30, 2021$21.50M+4351.8%
Q2 FY2020Jun 30, 2020$20.90M–
Q2 FY2019Jun 30, 2019$1.56M–
Q2 FY2018Jun 30, 2018$2.35M–
Q2 FY2017Jun 30, 2017$483.00K–

More RedHill Biopharma figures

See a number that looks wrong?